MCID: OVR044
MIFTS: 55

Ovarian Carcinosarcoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Ovarian Carcinosarcoma

MalaCards integrated aliases for Ovarian Carcinosarcoma:

Name: Ovarian Carcinosarcoma 11 19 58 14 16
Ovarian Malignant Mixed Epithelial Mesenchymal Tumor 19 58
Malignant Mixed Mullerian Tumor of the Ovary 19 58
Ovarian Malignant Mixed Mullerian Tumor 11 58
Mmmt of the Ovary 19 58
Malignant Mixed Müllerian Tumor of the Ovary 19
Ovarian Malignant Mesodermal Mixed Tumor 11
Ovarian Malignant Mixed Müllerian Tumor 19
Carcinosarcoma of Ovary 71
Ovarian Mmmt 11

Characteristics:


Prevelance:

Malignant Mixed Mullerian Tumor of the Ovary: 1-9/1000000 (Europe) 58

Age Of Onset:

Malignant Mixed Mullerian Tumor of the Ovary: Adult 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:6170
NCIt 49 C9192
SNOMED-CT 68 702368000
ICD10 via Orphanet 32 C56
UMLS via Orphanet 72 C0392998
Orphanet 58 ORPHA213512
UMLS 71 C0392998

Summaries for Ovarian Carcinosarcoma

GARD: 19 Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of Ovarian carcinosarcoma is not yet understood.

MalaCards based summary: Ovarian Carcinosarcoma, also known as ovarian malignant mixed epithelial mesenchymal tumor, is related to ovarian mesodermal adenosarcoma and bilateral breast cancer. An important gene associated with Ovarian Carcinosarcoma is H2AC18 (H2A Clustered Histone 18), and among its related pathways/superpathways are Disease and GPCR Pathway. The drugs Topotecan and Niraparib have been mentioned in the context of this disorder. Affiliated tissues include ovary, uterus and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased viability in pancreas lineage

Orphanet: 58 Malignant mixed Müllerian tumor of the ovary is a rare and very aggressive neoplasm presenting most commonly in postmenopausal women and is composed of adenocarcinomatous and sarcomatous elements and, depending on the types of these elements, can be classified as homologous or heterologous. It often has a poor prognosis.

Disease Ontology: 11 A malignant ovarian surface epithelial-stromal neoplasm that is a mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Related Diseases for Ovarian Carcinosarcoma

Diseases related to Ovarian Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 411)
# Related Disease Score Top Affiliating Genes
1 ovarian mesodermal adenosarcoma 31.6 WT1 PAX8
2 bilateral breast cancer 30.3 TP53 ERBB2 BRCA2 BRCA1
3 malignant teratoma 30.3 WT1 TP53 MIR371A
4 mature teratoma 30.2 TP53 MIR371A H2AC18
5 teratoma 30.0 TP53 MIR371A KRAS ERBB2
6 appendix adenocarcinoma 29.8 TP53 KRAS HRAS
7 papillary cystadenocarcinoma 29.8 WT1 TP53
8 cystic teratoma 29.8 TP53 PAX8
9 colon adenocarcinoma 29.7 TP53 PIK3CA KRAS HRAS ARID1A
10 leiomyosarcoma 29.6 WT1 TP53 BRCA1
11 plasma cell neoplasm 29.5 TP53 PIK3CA KRAS HRAS
12 vulva cancer 29.5 TP53 PIK3CA HRAS ERBB2
13 exanthem 29.4 KRAS HRAS H2AC18 ERBB2
14 myeloma, multiple 29.3 TP53 PIK3CA KRAS HRAS H2AC18
15 papillary adenocarcinoma 29.3 TP53 PAX8 KRAS HRAS ERBB2 BRCA1
16 glioblastoma 29.3 TP53 PIK3CA KRAS HRAS ERBB2 BRCA2
17 carcinosarcoma 29.2 WT1 TP53 PPP2R1A PIK3CA PAX8 KRAS
18 squamous cell carcinoma 29.2 TP53 PIK3CA KRAS HRAS ERBB2
19 adenocarcinoma 29.0 TP53 PIK3CA KRAS HRAS ERBB2 BRCA2
20 sarcoma 29.0 WT1 TP53 PIK3CA KRAS HRAS
21 cowden syndrome 28.8 TP53 PIK3CA KRAS HRAS ERBB2 BRCA2
22 rhabdomyosarcoma 28.7 WT1 TP53 PIK3CA KRAS HRAS ERBB2
23 uterine carcinosarcoma 28.6 TP53 PPP2R1A PIK3CA KRAS HRAS H2AC18
24 papillary serous adenocarcinoma 28.6 WT1 TP53 PAX8 KRAS HRAS ERBB2
25 cystadenocarcinoma 28.6 WT1 TP53 PAX8 KRAS BRCA2 BRCA1
26 ovarian cancer 28.1 WT1 TP53 TACSTD2 PPP2R1A PIK3CA KRAS
27 ovary adenocarcinoma 27.6 WT1 TP53 PIK3CA PAX8 KRAS HRAS
28 serous cystadenocarcinoma 27.6 WT1 TP53 PPP2R1A PIK3CA PAX8 KRAS
29 mixed cell type cancer 27.3 WT1 TP53 PPP2R1A PIK3CA PAX8 KRAS
30 tetraploidy 10.3 TP53 BRCA2
31 hereditary site-specific ovarian cancer syndrome 10.3 BRCA2 BRCA1
32 ovary transitional cell carcinoma 10.3 BRCA2 BRCA1
33 cancerophobia 10.3 BRCA2 BRCA1
34 nosophobia 10.3 BRCA2 BRCA1
35 rare tumor 10.3
36 breast-ovarian cancer, familial 2 10.3 BRCA2 BRCA1
37 esophagus verrucous carcinoma 10.3 TP53 PIK3CA
38 hereditary breast cancer 10.3 BRCA2 BRCA1
39 fanconi anemia, complementation group n 10.3 BRCA2 BRCA1
40 penile benign neoplasm 10.3 TP53 PIK3CA
41 small-cell carcinoma of the ovary of hypercalcemic type 10.3 TP53 ARID1A
42 cowden syndrome 5 10.3 PIK3CA H2AC18
43 inguinal hernia 10.2
44 enterocele 10.2
45 lung oat cell carcinoma 10.2 TP53 PIK3CA
46 vulvar sebaceous carcinoma 10.2 TP53 PAX8
47 clear cell adenofibroma 10.2 PIK3CA ARID1A
48 endometrial squamous cell carcinoma 10.2 TP53 PAX8
49 breast-ovarian cancer, familial 1 10.2 BRCA2 BRCA1
50 polyposis syndrome, hereditary mixed, 1 10.2 BRCA2 BRCA1

Graphical network of the top 20 diseases related to Ovarian Carcinosarcoma:



Diseases related to Ovarian Carcinosarcoma

Symptoms & Phenotypes for Ovarian Carcinosarcoma

GenomeRNAi Phenotypes related to Ovarian Carcinosarcoma according to GeneCards Suite gene sharing:

25 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.05 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.05 KRAS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.05 WT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.05 BRCA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.05 BRCA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10.05 WT1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.05 WT1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.05 ERBB2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.05 PAX8
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.05 ARID1A BRCA1 ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.05 ARID1A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.05 ARID1A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.05 ARID1A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.05 HRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.05 BRCA1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.05 ERBB2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.05 BRCA1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.05 ARID1A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.05 WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.05 KRAS
21 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.05 HRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.05 WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.05 ERBB2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.05 ARID1A WT1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.05 WT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.05 ERBB2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.05 ERBB2 KRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.05 ARID1A
29 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.05 H2AC18
30 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.05 HRAS
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.05 ERBB2 WT1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.05 ERBB2 HRAS
33 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.05 H2AC18
34 Decreased viability in pancreas lineage GR00235-A 8.96 ARID1A TP53

MGI Mouse Phenotypes related to Ovarian Carcinosarcoma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.32 ARID1A BRCA1 BRCA2 ERBB2 HRAS KRAS
2 homeostasis/metabolism MP:0005376 10.32 ARID1A ARID1B BRCA1 BRCA2 ERBB2 HRAS
3 normal MP:0002873 10.27 ARID1A BRCA1 BRCA2 ERBB2 HRAS KRAS
4 growth/size/body region MP:0005378 10.27 ARID1A ARID1B BRCA1 BRCA2 ERBB2 HRAS
5 nervous system MP:0003631 10.26 ARID1A ARID1B BRCA1 BRCA2 ERBB2 HRAS
6 endocrine/exocrine gland MP:0005379 10.22 ARID1A BRCA1 BRCA2 ERBB2 HRAS KRAS
7 muscle MP:0005369 10.19 ARID1A ARID1B BRCA1 ERBB2 HRAS KRAS
8 embryo MP:0005380 10.16 ARID1A BRCA1 BRCA2 ERBB2 KRAS PAX8
9 no phenotypic analysis MP:0003012 10.11 ARID1A HRAS KRAS PAX8 PIK3CA TP53
10 cellular MP:0005384 10.1 ARID1A BRCA1 BRCA2 ERBB2 KRAS PAX8
11 renal/urinary system MP:0005367 10.09 ARID1B BRCA1 HRAS KRAS PAX8 TP53
12 cardiovascular system MP:0005385 10.07 ARID1A ARID1B BRCA1 ERBB2 HRAS KRAS
13 behavior/neurological MP:0005386 10.06 ARID1B BRCA1 BRCA2 ERBB2 HRAS KRAS
14 limbs/digits/tail MP:0005371 10 BRCA1 BRCA2 ERBB2 KRAS PAX8 TP53
15 reproductive system MP:0005389 10 ARID1A ARID1B BRCA1 BRCA2 ERBB2 KRAS
16 digestive/alimentary MP:0005381 9.98 BRCA1 BRCA2 ERBB2 HRAS KRAS PIK3CA
17 skeleton MP:0005390 9.81 ARID1A BRCA1 BRCA2 ERBB2 HRAS KRAS
18 mortality/aging MP:0010768 9.77 ARID1A ARID1B BRCA1 BRCA2 ERBB2 HRAS
19 integument MP:0010771 9.28 ARID1B BRCA1 BRCA2 ERBB2 HRAS KRAS

Drugs & Therapeutics for Ovarian Carcinosarcoma

Drugs for Ovarian Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60699 60700
2
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
3
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
4
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
7
Ifosfamide Approved Phase 3 3778-73-2 3690
8
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
9
Palifosfamide Investigational Phase 3 31645-39-3 100427
10 Liposomal doxorubicin Phase 2, Phase 3
11 Alkylating Agents Phase 3
12 Antineoplastic Agents, Alkylating Phase 3
13 Albumin-Bound Paclitaxel Phase 3
14 Antimitotic Agents Phase 3
15 Tubulin Modulators Phase 3
16
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
17
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
18
Aflibercept Approved Phase 2 862111-32-8 124490314
19
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
20
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
21
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
22
Iodine Approved, Investigational Phase 2 7553-56-2 807
23
Aldesleukin Approved Phase 2 110942-02-4
24
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
25
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
26
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
27
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
28
MK-1775 Investigational Phase 2 955365-80-7 24856436
29 Liver Extracts Phase 2
30 Antifungal Agents Phase 2
31 Anti-Bacterial Agents Phase 2
32 Antibiotics, Antitubercular Phase 2
33 topoisomerase I inhibitors Phase 2
34 Anti-Retroviral Agents Phase 2
35 Anti-HIV Agents Phase 2
36 Antiviral Agents Phase 2
37 Anti-Infective Agents Phase 2
38 Antimetabolites Phase 2
39 Immunosuppressive Agents Phase 2
40 Antirheumatic Agents Phase 2
41 Interleukin-2 Phase 2
42 Analgesics, Non-Narcotic Phase 2
43 Analgesics Phase 2
44 Pharmaceutical Solutions Phase 2
45 Tin Fluorides Phase 2
46 Immunologic Factors Phase 2
47 Immunoglobulins, Intravenous Phase 2
48 Immunoglobulins Phase 2
49 Immunoglobulin G Phase 2
50 Halichondrin B Phase 2 5915307

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy Recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
2 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) Completed NCT02993705 Phase 2 Trabectedin
4 Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
5 A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas Completed NCT00390234 Phase 2 ziv-aflibercept
6 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
7 MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
8 Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine
9 A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
10 Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Active, not recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
11 An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Active, not recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
12 The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma Not yet recruiting NCT05619913 Phase 2 Eribulin Mesylate;Pembrolizumab
13 Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion Not yet recruiting NCT04919629 Phase 2
14 A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma Withdrawn NCT04149275 Phase 2 Cabozantinib;Ipilimumab;Nivolumab
15 A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
16 A Phase I Trial of Dose Dense (Biweekly) Carboplatin Combined With Paclitaxel and Pegfilgrastim (Neulasta): A Feasibility Study in Patients With Untreated Stage III and IV Ovarian, Tubal or Primary Peritoneal Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
17 A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
18 A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) Recruiting NCT04092270 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride;Peposertib
19 Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) Recruiting NCT02020707 Phase 1 Nab-paclitaxel
20 A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers Terminated NCT03924245 Phase 1 Entinostat;Olaparib
21 A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT01080521
22 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors - A Randomized Controlled Trial Terminated NCT03641287

Search NIH Clinical Center for Ovarian Carcinosarcoma

Genetic Tests for Ovarian Carcinosarcoma

Anatomical Context for Ovarian Carcinosarcoma

Organs/tissues related to Ovarian Carcinosarcoma:

MalaCards : Ovary, Uterus, Endothelial, Liver, Lymph Node, Small Intestine, Cervix

Publications for Ovarian Carcinosarcoma

Articles related to Ovarian Carcinosarcoma:

(show top 50) (show all 172)
# Title Authors PMID Year
1
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin. 62
36206301 2022
2
Cutaneous metastasis of carcinomatous component of ovarian carcinosarcoma: A case report and review of the literature. 62
36199118 2022
3
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26). 62
36220670 2022
4
Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. 62
35715633 2022
5
Management of a rare ovarian carcinosarcoma: A case report and literature review. 62
35949347 2022
6
[Ovarian Carcinosarcoma Associated with Cowden Syndrome-A Case Report]. 62
35851351 2022
7
Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma. 62
35949745 2022
8
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. 62
35007153 2022
9
Perspectives on Ovarian Cancer 1809 to 2022 and Beyond. 62
35453839 2022
10
Imaging in gynecological disease (23): clinical and ultrasound characteristics of ovarian carcinosarcoma. 62
34225386 2022
11
Genetic Analysis and Combined Therapy of Surgery and Chemotherapy for the Progression-Free Survival of a Patient with Ovarian Carcinosarcoma: A Case Report and Literature Review. 62
35791423 2022
12
Establishment and validation of a novel nomogram for survival prediction of ovarian carcinosarcoma. 62
35261884 2022
13
Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network. 62
35053517 2022
14
[Clinicopathological features of malignant mixed mesodermal tumor: analysis of 50 cases]. 62
34496490 2021
15
Aggressive Resection of Malignant Paraaortic and Pelvic Tumors Accompanied by Arterial Reconstruction with Synthetic Arterial Graft. 62
33931576 2021
16
Carcinosarcoma of the ovary: MR and clinical findings compared with high-grade serous carcinoma. 62
33216290 2021
17
T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review. 62
33927729 2021
18
Impact of Lymphadenectomy on Outcomes of Early-Stage Ovarian Cancer: A Systematic Review and Meta-Analysis. 62
34169090 2021
19
Clinical Nomograms for Predicting the Overall Survival and Cancer-specific Survival of patients with Ovarian Carcinosarcoma patients after Primary Surgery. 62
34729123 2021
20
Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma. 62
34938651 2021
21
Surgical management of ovarian carcinosarcoma with inferior vena cava extension into the right atrium. 62
33391655 2020
22
Ovarian Carcinosarcoma with Retroperitoneal Para-Aortic Lymph Node Dissemination Followed by an Unusual Postoperative Complication: A Case Report with a Brief Literature Review. 62
33322259 2020
23
Primitive ovarian carcinosarcoma: a clinical and radiological analysis of five cases. 62
33115531 2020
24
Ovarian malignant mixed Müllerian tumor: a rare case report from Tanzania. 62
33123343 2020
25
Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival. 62
32029291 2020
26
Detailed overview on rare malignant ovarian tumors. 62
32115180 2020
27
Should MMMT still be treated with adjuvant taxane-based combination chemotherapy? 62
31993743 2020
28
Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary. 62
31796530 2020
29
Cauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spread. 62
31893054 2019
30
Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience. 62
31766630 2019
31
Ovarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an Origin From the Fallopian Tube. 62
30913944 2019
32
A rare case of ovarian carcinosarcoma with squamous cell carcinoma. 62
30947745 2019
33
Ovarian carcinosarcoma: Current developments and future perspectives. 62
30771873 2019
34
Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study. 62
30640703 2019
35
Ovarian Teratoid Carcinosarcoma Is an Aggressive Tumor of Probable Mullerian Derivation with a Carcinosarcomatous and Mixed Germ-Cell Morphology. 62
31011323 2019
36
Significant Tumor Response to the Poly (ADP-ribose) Polymerase Inhibitor Olaparib in Heavily Pretreated Patient With Ovarian Carcinosarcoma Harboring a Germline RAD51D Mutation. 62
35135167 2018
37
Resection of a metastatic bulky subphrenic tumor for the treatment of advanced ovarian cancer using liver mobilization and the Pringle maneuver. 62
30139533 2018
38
Usefulness of ascites cytology for the evaluation of chemotherapy response in ovarian carcinosarcoma. 62
29488261 2018
39
Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment. 62
29143144 2018
40
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. 62
29426293 2018
41
Prognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma. 62
30022854 2018
42
Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. 62
30345126 2018
43
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma. 62
30147940 2018
44
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. 62
28679774 2017
45
Paraneoplastic cerebellar degeneration secondary to ovarian carcinosarcoma: a cerebellar conundrum. 62
28790096 2017
46
Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma. 62
28791266 2017
47
KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice. 62
28032649 2017
48
Extremely Locally Advanced Ovarian Malignant Mixed Mullerian Tumor in 37-Years-Old Female. 62
28593890 2017
49
Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. 62
28125702 2017
50
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. 62
27958685 2017

Variations for Ovarian Carcinosarcoma

Cosmic variations for Ovarian Carcinosarcoma:

8 (show top 50) (show all 514)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM90140159 TRAF7 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.1732G>A p.E578K 16:2175939-2175939 11
2 COSM144158749 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.512T>A p.L171H 17:7673539-7673539 11
3 COSM144315379 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.287G>A p.C96Y 17:7675208-7675208 11
4 COSM111836164 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.423C>T p.C141= 17:7675189-7675189 11
5 COSM144651337 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.616G>A p.G206S 17:7674230-7674230 11
6 COSM142559914 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.407G>A p.R136H 17:7675088-7675088 11
7 COSM145019014 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.598A>G p.N200D 17:7674248-7674248 11
8 COSM122762842 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.94A>G p.K32E 17:7675122-7675122 11
9 COSM87900846 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.380C>T p.S127F 17:7675232-7675232 11
10 COSM121875541 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.422G>A p.R141H 17:7673802-7673802 11
11 COSM122734335 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.337G>A p.G113S 17:7674230-7674230 11
12 COSM87898527 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.814G>A p.V272M 17:7673806-7673806 11
13 COSM144658149 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.287G>A p.C96Y 17:7675208-7675208 11
14 COSM143944147 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.265C>T p.R89W 17:7674221-7674221 11
15 COSM142838949 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.380C>T p.S127F 17:7675232-7675232 11
16 COSM144148837 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.-55C>T p.? 17:7675189-7675189 11
17 COSM143158810 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.-98C>T p.? 17:7675232-7675232 11
18 COSM105654789 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.490A>G p.K164E 17:7675122-7675122 11
19 COSM143943941 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.337G>A p.V113M 17:7673806-7673806 11
20 COSM143156843 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.266G>A p.R89Q 17:7674220-7674220 11
21 COSM121875983 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.347G>A p.R116Q 17:7674220-7674220 11
22 COSM87897711 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.818G>A p.R273H 17:7673802-7673802 11
23 COSM121876485 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.421C>T p.R141C 17:7673803-7673803 11
24 COSM142837497 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.733G>A p.G245S 17:7674230-7674230 11
25 COSM93183877 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.733G>A p.G245S 17:7674230-7674230 11
26 COSM122299085 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.94A>G p.K32E 17:7675122-7675122 11
27 COSM121876255 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.315G>A p.M105I 17:7674252-7674252 11
28 COSM143370575 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.701G>A p.R234H 17:7673802-7673802 11
29 COSM111758775 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.733G>A p.G245S 17:7674230-7674230 11
30 COSM93183281 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.818G>A p.R273H 17:7673802-7673802 11
31 COSM106053434 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.742C>T p.R248W 17:7674221-7674221 11
32 COSM112282360 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.490A>G p.K164E 17:7675122-7675122 11
33 COSM144087235 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.234G>A p.M78I 17:7674252-7674252 11
34 COSM144651292 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.697G>A p.V233M 17:7673806-7673806 11
35 COSM143371076 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.616G>A p.G206S 17:7674230-7674230 11
36 COSM106080940 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.490A>G p.K164E 17:7675122-7675122 11
37 COSM106124583 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.423C>T p.C141= 17:7675189-7675189 11
38 COSM144015546 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.347C>T p.S116F 17:7675232-7675232 11
39 COSM142846805 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.725G>C p.C242S 17:7674238-7674238 11
40 COSM122734300 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.418G>A p.V140M 17:7673806-7673806 11
41 COSM142560476 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.616G>A p.G206S 17:7674230-7674230 11
42 COSM145017865 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.616G>A p.G206S 17:7674230-7674230 11
43 COSM121876163 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.418G>A p.V140M 17:7673806-7673806 11
44 COSM143372002 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.598A>G p.N200D 17:7674248-7674248 11
45 COSM106053362 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.733G>A p.G245S 17:7674230-7674230 11
46 COSM145017944 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.625C>T p.R209W 17:7674221-7674221 11
47 COSM144312115 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.263C>T p.S88F 17:7675232-7675232 11
48 COSM142837469 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.814G>A p.V272M 17:7673806-7673806 11
49 COSM105619828 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.782+379G>A p.? 17:7673802-7673802 11
50 COSM122271559 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.347G>A p.R116Q 17:7674220-7674220 11

Expression for Ovarian Carcinosarcoma

Search GEO for disease gene expression data for Ovarian Carcinosarcoma.

Pathways for Ovarian Carcinosarcoma

Pathways related to Ovarian Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 TP53 PPP2R1A PIK3CA KRAS HRAS H2AC18
2
Show member pathways
13.64 TP53 PPP2R1A KRAS HRAS ERBB2 BRCA2
3
Show member pathways
13.47 BRCA1 ERBB2 HRAS KRAS PIK3CA PPP2R1A
4
Show member pathways
13.38 TP53 PIK3CA KRAS HRAS ERBB2 BRCA2
5
Show member pathways
12.86 TP53 KRAS HRAS BRCA2 BRCA1
6
Show member pathways
12.83 TP53 PPP2R1A PIK3CA KRAS HRAS BRCA1
7 12.76 PPP2R1A PIK3CA KRAS HRAS ERBB2
8
Show member pathways
12.61 TP53 PPP2R1A KRAS HRAS
9
Show member pathways
12.56 TP53 PPP2R1A PIK3CA KRAS HRAS
10
Show member pathways
12.54 PPP2R1A PIK3CA KRAS HRAS
11
Show member pathways
12.51 PPP2R1A PIK3CA KRAS HRAS
12
Show member pathways
12.5 TP53 PIK3CA KRAS HRAS ERBB2
13
Show member pathways
12.47 BRCA2 ERBB2 HRAS KRAS PIK3CA TP53
14 12.46 TP53 PPP2R1A BRCA2 BRCA1
15
Show member pathways
12.4 ERBB2 HRAS PIK3CA TP53
16
Show member pathways
12.33 PIK3CA KRAS HRAS BRCA1
17
Show member pathways
12.32 TP53 PIK3CA KRAS HRAS ERBB2
18
Show member pathways
12.27 TP53 PIK3CA KRAS HRAS ERBB2
19
Show member pathways
12.2 PPP2R1A PIK3CA KRAS HRAS
20
Show member pathways
12.18 PIK3CA KRAS HRAS ERBB2
21 12.11 TP53 PIK3CA KRAS HRAS
22 12.07 BRCA1 BRCA2 KRAS TP53
23
Show member pathways
12.06 TP53 PIK3CA KRAS HRAS ERBB2
24
Show member pathways
11.99 PPP2R1A KRAS HRAS
25
Show member pathways
11.99 PIK3CA KRAS HRAS ERBB2
26
Show member pathways
11.98 TP53 PIK3CA ERBB2
27 11.94 PPP2R1A KRAS HRAS
28 11.94 HRAS KRAS PIK3CA
29
Show member pathways
11.93 PIK3CA KRAS HRAS ERBB2
30
Show member pathways
11.93 TP53 PIK3CA KRAS HRAS ERBB2 BRCA2
31
Show member pathways
11.87 PIK3CA KRAS HRAS
32
Show member pathways
11.87 PIK3CA KRAS HRAS
33
Show member pathways
11.86 TP53 BRCA2 BRCA1
34
Show member pathways
11.86 KRAS HRAS ARID1B ARID1A
35
Show member pathways
11.85 PIK3CA KRAS HRAS
36
Show member pathways
11.84 PIK3CA KRAS HRAS ERBB2
37
Show member pathways
11.82 PIK3CA KRAS HRAS
38
Show member pathways
11.79 PIK3CA KRAS HRAS
39 11.77 TP53 PIK3CA HRAS
40
Show member pathways
11.77 TP53 BRCA2 BRCA1
41 11.75 TP53 BRCA2 BRCA1
42
Show member pathways
11.74 PIK3CA KRAS HRAS
43
Show member pathways
11.71 PIK3CA KRAS HRAS
44 11.66 TP53 PIK3CA KRAS HRAS ERBB2
45
Show member pathways
11.6 PIK3CA KRAS HRAS
46
Show member pathways
11.6 TP53 PIK3CA KRAS HRAS
47
Show member pathways
11.58 PIK3CA HRAS ERBB2
48 11.56 ERBB2 HRAS KRAS
49
Show member pathways
11.52 PIK3CA KRAS HRAS
50 11.42 TP53 PIK3CA KRAS HRAS ERBB2

GO Terms for Ovarian Carcinosarcoma

Cellular components related to Ovarian Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear ubiquitin ligase complex GO:0000152 9.26 BRCA2 BRCA1
2 DNA packaging complex GO:0044815 9.16 ARID1B ARID1A
3 SWI/SNF superfamily-type complex GO:0070603 8.62 ARID1B ARID1A

Biological processes related to Ovarian Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular senescence GO:0090398 9.95 TP53 HRAS BRCA2
2 negative regulation of cell growth GO:0030308 9.86 BRCA1 PPP2R1A TP53 WT1
3 positive regulation of gene expression GO:0010628 9.85 WT1 TP53 KRAS HRAS ERBB2 BRCA1
4 cellular response to ionizing radiation GO:0071479 9.8 TP53 BRCA2 BRCA1
5 positive regulation of DNA-templated transcription GO:0045893 9.8 WT1 TP53 PAX8 BRCA2 BRCA1 ARID1B
6 cellular response to gonadotropin stimulus GO:0071371 9.76 WT1 PAX8
7 metanephric S-shaped body morphogenesis GO:0072284 9.71 WT1 PAX8
8 metanephric epithelium development GO:0072207 9.67 WT1 PAX8
9 chordate embryonic development GO:0043009 9.61 BRCA2 BRCA1
10 transcription initiation-coupled chromatin remodeling GO:0045815 9.1 TP53 ARID1B ARID1A

Molecular functions related to Ovarian Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein serine/threonine kinase activator activity GO:0043539 8.8 PIK3CA KRAS HRAS

Sources for Ovarian Carcinosarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....